Researchers have harnessed synthetic biology to engineer chimeric antigen receptor (CAR) T cells that precisely target and destroy cancer. However, these powerful cells can also attack healthy tissues ...

For solid tumors, CAR T cell therapy has struggled because the therapeutic cells cannot access their target efficiently due to the suppressive tumor microenvironment (TME). Finally, since many of the ...

The success of CAR T-cell therapy in leukemias and lymphomas contrasts with its limited efficacy in solid tumors. These barriers include an immunosuppressive tumor microenvironment, tumor ...

"By recreating key aspects of the lymph node microenvironment, our hydrogels provide biochemical and mechanical cues necessary for enhanced CAR expression and T cell proliferation," explains ...

CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satricabtagene ... to target cancer cells, as well as infiltrate and survive in the hostile microenvironment of the tumour.